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To evaluate the predictive value of a panel of gene polymorphisms involved in metabolism of 5-FU and cisplatin on clinical outcome
in advanced gastric cancer patients. A total of 52 patients were enrolled in this study. DNA was extracted from paraffin-embedded
tumour specimen. Genotypes were determined using PCR-RFLP. Median survival time was 6.0 months (95% CI 3.9;8.1). Overall
response rate was 26%. Patients possessing the glutathione S-transferase P1-105 Valine/Valine (GSTP1-105VV) genotype showed a
response rate of 67% compared to 21% in patients harbouring at least one GSTP1-105 Isoleucine (GSTP1-105I) allele (P¼0.038).
GSTP1-105VV patients demonstrated a significant superior median survival time of 15.0 months (95% CI 7.8;22.0) compared to 6.0
months (95% CI 5.1;7.0) in patients with at least one GSTP1-105I allele (P¼0.037). Patients possessing a favourable thymidylate
synthase (TS) genotype (2R/2R, 2R/3RC, 3RC/3RC) experienced a superior survival time of 10.2 months (95% CI 5.1;15.3)
compared to 6.0 months (95% CI 5.0;7.0) in patients with unfavourable TS genotypes (P¼0.099). Patients harbouring the GSTP1-
105II genotype and one of the unfavourable TS genotypes showed an inferior median survival time of 6.0 months (95% CI 3.9;8.1)
compared to 11 months (95% CI 6,23;15,77) in patients with either GSTP1-105VV or a favourable TS genotype (P¼0.044). Testing
for TS and GSTP1 polymorphisms may allow identification of gastric cancer patients who will benefit from 5-FU/cisplatin
chemotherapy, sparing others the side effects of this chemotherapy.
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Worldwide, gastric cancer is the fourth common type of cancer
and the second most frequent cause of death from cancer. The
median survival time of patients with advanced gastric cancer
ranges approximately from 7.5 to 12 months (Parkin, 2001). 5-FU/
cisplatin has been referred to as a standard chemotherapy in
gastric cancer patients for many years. During the last few years
additional drugs were introduced into chemotherapy regimens for
gastric cancer such as oxaliplatin, the taxanes and irinotecan.
Results from phase II studies indicate a promising efficacy and
managable toxicity profile for combination chemotherapies
including these new substances (Al-Batran et al, 2004; Bouche
et al, 2004; Chao et al, 2004; Lee et al, 2004; Park et al, 2004;
Souglakos et al, 2004; Van Cutsem, 2004). One of the remaining
challenges is the development of predictive marker profiles to
identify patients who will derive both minimal toxicity and
maximum benefit from certain chemotherapy.
There is a growing body of evidence suggesting that genetic
polymorphisms in genes involved in metabolism, signalling,
transport, DNA-repair and cellular response pathways all con-
tribute to inter-patient variability of drug response and toxicity.
Pharmacogenetic analyses appear to be a promising tool to
develop individualised treatment plans.
Fluoropyrimidines remain an important drug in the chemother-
apeutic treatment of gastric cancer. Decreased levels of the target
enzyme thymidylate synthase (TS) have been repeatedly associated
with superior clinical outcome in gastrointestinal cancers, includ-
ing stomach cancer (Leichman et al, 1995; Boku et al, 1998; Shirota
et al, 2001). TS catalyses the formation of thymidylate, a source of
DNA replication, from dUMP (Danenberg, 1977). A repeat
polymorphism within the 50 untranslated region (UTR), that alters
TS expression was correlated with response and survival in
colorectal cancer patients receiving 5-FU in several studies (Horie
et al, 1995; Kawakami et al, 1999; Iacopetta et al, 2001; Pullarkat
et al, 2001; Marsh et al, 2001). Recently, a novel functional G/C
single nucleotide polymorphism (SNP) within this repeat poly-
morphism was identified (Kawakami and Watanabe, 2003;
Mandola et al, 2003). This G/C SNP causes a disruption of the
binding site of the transcription factor USF-1 thereby altering TS
expression. A recent report in colorectal cancer indicates the
clinical significance of the G/C SNP (Marcuello et al, 2004). Finally,
a 6-bp deletion polymorphism within the 30 UTR of the TS gene
has been described (Ulrich et al, 2000) that also alters TS
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sexpression, although the exact underlying mechanism remains
unclear at this time (Mandola et al, 2004). In addition to
polymorphisms of the TS gene, the common MTHFR-C677T
polymorphism has been associated with response to 5-FU in
colorectal tumours (Cohen et al, 2003; Etienne et al, 2004).
Methylene tetrahydrofolate reductase (MTHFR) plays a central
role in folate metabolism. The substrate for MTHFR, 5,10-MTHF,
is used for the synthesis of dTMP by TS.
Glutathione-S-transferases are crucial for the cell defence
system. These phase II detoxification enzymes are involved in
detoxification of a variety of chemotherapeutics including
platinum. The GSTP1 isoform has been detected at high levels
within the gastrointestinal tract. In addition, in vitro analyses
revealed a significant association between high GSTP1 expression
of tumour cells and decreased sensitivity to platinum agents (Oguri
et al, 2000). An A/G SNP located within the substrate-binding
domain of GSTP1, at position þ313 within exon 5, results in an
amino-acid substitution of Isoleucine by Valine (Ile105Val). This
polymorphism significantly influences enzyme activity (Zimniak
et al, 1994) and is linked to clinical outcome of patients who
received platinum-based chemotherapy (Stoehlmacher et al, 2002,
2004). GSTM1 and GSTT1 deletion polymorphisms (null geno-
types) have also been reported to be associated with diminished
GST enzyme activity (London et al, 2000).
Genes of the nucleotide-excision-repair (NER) pathway plays
a key role in recognition and repair of damaged DNA caused
by platinum compounds. Important members of the NER pathway,
namely excision-repair-cross-complementing gene 1 and 2 (ERCC1
and ERCC2), the latest also named Xeroderma pigmentosum
complementation group D (XPD) exhibit several polymorphic
sites. Functional polymorphisms of both genes (ERCC1 – C118T
and ERCC2 – Gln751Lys) have been demonstrated to impact
clinical outcome of patients receiving platinum-based chemother-
apy (Shen et al, 1998; Park et al, 2001; Isla et al, 2004).
In the current analysis, we studied a panel of nine genetic
polymorphisms within seven genes (TS, MTHFR, GSTP1, GSTT1,
GSTM1, ERCC1, ERCC2) involved in the metabolism of cisplatin
and 5-FU as well as genes of the NER. We tested the hypothesis
whether these polymorphisms, alone or in combination, may have
the potential to predict response and survival in patients with
advanced gastric cancer receiving 5-FU/cisplatin combination
chemotherapy.
PATIENTS AND METHODS
Subjects
All patients included in this study had advanced gastric cancer and
were treated between 2002 and 2004 at the Department of
Oncology at the University Hospital Hamburg Eppendorf,
Germany. All patients received at least one complete cycle of 5-
FU/cisplatin/FA as first-line chemotherapy. One cycle consisted of
biweekly cisplatin 50mgm
 2 (1h infusion) and weekly FU 2gm
 2
(24h continuous infusion) and FA 500mgm
 2 (2-h intravenous
infusion) for 6 weeks. Response evaluation was performed every 6
weeks using CT scanning based on RECIST criteria. Responses
were confirmed after 4 weeks. All patients agreed to perform
genotype analyses in this study.
Extraction of DNA
Paraffin-embedded tumour specimens for genotype analyses were
available from 52 patients with advanced gastric cancer. Genomic
DNA was extracted from representative sections (at least 80% of
tumour infiltration) of formalin-fixed, paraffin-embedded tumour
specimen using the QiaAmp kit (Qiagen, Valencia, CA, USA).
Representative tumour sections were selected after evaluation
(light microscopy) by the pathologist (CW).
Study design
Genotyping was carried out by using PCR-based RFLP protocols as
described previously. The following genetic polymorphisms were
analysed: glutathione S-transferase (GSTP1 – Ile105Val, GSTT1
and GSTM1 deletion), thymidylate synthase (TS-50 UTR 2R/3R;
TS-50 G/C; TS-30 UTR 1494del6), methylene-tetrahydofolate-
reductase (MTHFR – C677T), excision repair cross-complement-
ing gene 1 and 2 (ERCC1 – C118T and ERCC2 – Gln751Lys) (Frosst
et al, 1995; Arand et al, 1996; Lunn et al, 2000; Mandola et al, 2003;
Stoehlmacher et al, 2004). The PCR reaction volume was 25ml and
restricted PCR fragments were separated on a 3% agarose gel. PCR/
RFLP analyses were performed by a technician blinded for the
clinical data. For quality purposes 20% random samples of each
genotype were repeated.
A comprehensive chart review was performed to obtain all
necessary demographic and clinical information including age,
sex, involved metastatic sites, objective tumour response rate and
survival. Survival was measured from the beginning of 5-FU/
cisplatin chemotherapy until death from any cause.
Statistical analyses
Statistical analyses were carried out using SPSS for Windows
(Version 13.0). Fisher’s exact test (two-sided) and w
2 test were used
to assess the association between each genotype and clinical
response to 5-FU/cisplatin chemotherapy. The log-rank test
(Miller, 1981) and Kaplan–Meier plots (Kaplan and Meier, 1958)
were used to evaluate the association of genotypes and overall
survival. Statistical significance was interpreted as Po0.05.
RESULTS
In this retrospective study, 52 Caucasian patients consisting of 18
females (35%) and 34 males (65%) were analysed. Patients’
demographics and disease characteristics at baseline are given in
Table 1. The median follow-up time was 6.2 months (95% CI 4.6;
7.4). Median survival time was 6.0 months (95% CI 3.9; 8.1). None
of these patients were referred for definitive surgery after
application of chemotherapy. Two patients were excluded from
response evaluation, because the response confirmation after 4
weeks was not documented in the medical chart. In all, 26% of
patients (13/50) showed a response (partial response (PR) or
complete response (CR)) to 5-FU/cisplatin chemotherapy. The
majority of patients (37/50, 74%) demonstrated stable disease (SD)
or progressive disease (PD).
Genotypes could be determined as follows: GSTP1 50/52 (96%),
GSTM1 and GSTT1 52/52 (100%), ERCC1 51/52 (98%), ERCC2 51/
52 (98%), MTHFR-677 52/52 (100%), TS-50 UTR 45/52 (87%), TS-
50 UTR G-C SNP 43/52 (83%) and TS-30 41/52 (79%). Distribution
of genotypes and responses of the available 50 patients is given in
Table 2.
Association between GSTP1-105 polymorphism and
response and survival
GSTP1-105 genotype analyses were successful for 50 patients of
which 48 were eligible for response analyses.
For association analysis of genotype and response to che-
motherapy patients with CR and PR were determined ‘responders’
and patients with SD and PD were referred to as ‘nonresponders’.
According to previous data (Stoehlmacher et al, 2004) patients
were divided into a favourable (homozygous GSTP1-105Val) and
an unfavourable genotype group (heterozygots and homozygous
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type showed a significant superior response rate of 67% (4/6)
compared to only 21% (9/42) in patients harbouring at least one
GSTP1-105Ile allele (P¼0.038, Fisher’s exact test) (Table 3). None
of the patients homozygous for the GSTP1-105Val allele showed
disease progression.
Patients with GSTP1-105 Val/Val genotype demonstrated
significant superior median survival time with 15.0 months (95%
CI 7.8; 22.0) compared to only 6.0 months (95% CI 5.1; 7.0) for
patients with at least one GSTP1-105Ile allele (P¼0.038, log-rank
test) (Figure 1).
Association between TS polymorphisms and outcome to
5-FU/cisplatin chemotherapy
Both, the TS-30 UTR (6-bp deletion) polymorphism and the
polymorphisms in the 50 UTR (28bp repeat þ G/C SNP) were not
associated with response to chemotherapy.
However, combined analysis of polymorphisms in the TS-50
UTR showed a trend for superior survival in patients harbouring a
favourable TS-50 UTR genotype. The favourable TS-50 UTR
genotype group included those genotypes that have been linked
to decreased TS expression; 2R/2R, 2R/3RC, 3RC/3RC. Whereas
the unfavourable group consisted of TS genotypes associated with
elevated TS levels: 2R/3RG, 3RC/3RG and 3RG/3RG (Mandola et al,
2003; Marcuello et al, 2004). The favourable group experienced a
superior median survival time of 10.2 months (95% CI 5.1; 15.3)
compared to only 6.0 months (95% CI 5.0; 7.0) in the unfavourable
genotype group (P¼0.099, log-rank test).
Combined analysis of GSTP1 and TS-50 genotypes and
survival
Based on the results of superior survival observed for the
favourable GSTP1-105 genotype group and the favourable TS-50
UTR genotype group in the univariate analysis, a combined
analysis for survival was performed.
All genotypes (GSTP1-105, TS-50 repeat and TS50-SNP) could be
identified in 41 of 52 patients (79%). Patients were divided into
three groups: patients possessing neither GSTP1 Val/Val nor one
of the favourable TS-50 UTR genotypes (group A, n¼15 (37%)),
patients harbouring either GSTP1 Val/Val or a favourable TS-50
UTR genotype (group B, n¼23 (56%)) and patients with GSTP1-
105 Val/Val and a favourable TS-50 UTR genotype (group C, n¼3
(7%)). Owing to the small size of group C, this group was
combined with group B for survival analyses. Group B and C
patients combined demonstrated a superior median survival time
of 11.0 months (95% CI 6,23; 15,77) compared to only 6.0 months
Table 1 Patient’s demographics and disease characteristics at baseline
n %
Age (years) 56 —
Range 27–82 —
Gender
Male 34 65
Female 18 35
Karnofski index
100–90 27 52
80–70 25 48
Number of involved sites
17 1 3
21 8 3 5
X32 7 5 2
Previous surgery
Yes 37 71
No 15 29
Prior adjuvant chemotherapy
Yes 3 6
No 49 94
Table 2 Distribution of genotypes and responses
Responder Nonresponder
Total n (%) n (%) n (%) P-value
a
All 50 (100) 13 (26) 37 (74) —
TS-50UTR
2R/2R 13 (26) 2 (15) 11 (85)
2R/3R 19 (38) 7 (37) 12 (63)
3R/3R 12 (24) 3 (25) 9 (75) 0.400
Missing 6 (12)
TS-50 UTR+G/C SNP
2/2, 2/3C, 3C/3C 23 (46) 5 (22) 18 (78)
2/3G, 3C/3G, 3G/3G 20 (40) 7 (35) 13 (65) 0.334
Missing 7 (14)
TS-30 1494del6
 6/ 6 12 (24) 5 (42) 7 (58)
 6/6 23 (46) 6 (26) 17 (74)
6/6 5 (10) 1 (20) 4 (80) 0.553
Missing 10 (20)
GSTP1–105
Ile/Ile 30 (60) 7 (23) 23 (77)
Ile/Val 12 (24) 2 (17) 10 (83)
Val/Val 6 (12) 4 (67) 2 (33) 0.060
Missing 2 (4)
GSTM1
GSTM1  32 (64) 9 (28) 23 (72)
GSTM1+ 18 (36) 4 (22) 14 (78) 0.648
Missing 0 (0)
GSTT1
GSTT1  38 (76) 8 (21) 30 (79)
GSTT1+ 12 (24) 5 (42) 7 (58) 0.156
Missing 0 (0)
ERCC1–118
C/C 5 (10) 2 (40) 3 (60)
C/T 26 (52) 6 (23) 20 (77)
T/T 18 (36) 5 (28) 13 (72) 0.727
Missing 1 (2)
ERCC2–751
Gln/Gln 12 (24) 3 (25) 9 (75)
Gln/Lys 25 (50) 8 (32) 17 (68)
Lys/Lys 12 (24) 2 (17) 10 (83) 0.607
Missing 1 (2)
MTHFR-677
C/C 28 (56) 10 (36) 18 (64)
C/T 20 (40) 2 (10) 18 (90)
T/T 2 (4) 1 (50) 1 (50) 0.099
Missing 0 (0)
50 of 52 patients (96%) were evaluable for response. Two pts were excluded for
response evaluation due to missing response confirmation (MRC). For association
analysis of genotype and response to chemotherapy patients with complete response
(CR) and partial response (PR) were determined ‘responder’ and patients with stable
disease (SD) and progressive disease (PD) were referred to as ‘non-responder’.
aw
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Figure 2). Two patients of group C were still alive at time of
analyses with a survival time of 18 and 22 months, respectively.
The third patient of this group died 15 months after start of 5-FU/
cisplatin chemotherapy.
No associations between any of the polymorphisms TS-30
1494del6, MTHFR – C677T, GSTM1, GSTT1, ERCC1 – C118T or
ERCC2 – Gln751Lys and response (Table 2) or overall survival
were found.
DISCUSSION
We attempted to identify predictive genetic polymorphisms for
response and survival to 5-FU/cisplatin chemotherapy in patients
with advanced gastric cancer. In our study, the GSTP1-105
polymorphism was identified as a predictive and a prognostic
marker in gastric cancer patients. Cisplatin (CDDP), widely used in
the treatment of solid tumours, is in part detoxified by glutathione
S-transferase P1 (GSTP1). The GSTP1-105Val allele was signifi-
cantly associated with increased response rate and superior
survival in the current study. The insufficient formation of
CDDP-Glutathione (CDDP-GSH) adducts, the detoxified form of
CDDP, was postulated as mechanism for the protective effect of the
GSTP1-105Val variant. Goto et al (1999) provided evidence for the
direct involvement of GSTP1 in the detoxification of CDDP by
forming CDDP-GSH adducts. Transfection of GSTP1 cDNA into
human colon cancer cells resulted in an increase of GSTP1
expression and an augmentation of DDP-GSH adduct formation
(Goto et al, 1999). In addition, transfection analyses reported by
Ban et al (1996) showed an association between GSTP1 and both
acquired and intrinsic resistance to cisplatin (Ban et al, 1996). As a
result of impairment of the GSTP1 substrate binding capacity
caused by the underlying A-G substitution, patients homozygous
for the GSTP1-105 valine variant may accumulate more drug
compared to patients possessing one or two wild-type alleles
(Watson et al, 1998). These results are in agreement with reports
linking high GSTP1 mRNA expression to improved survival in
oesophageal cancer patients. Among patients with oesophageal
cancer, who received a 5-FU/cisplatin combination chemotherapy
and radiation, those patients with decreased intratumoral GSTP1
levels demonstrated significant superior survival (Joshi et al,
2005). Additionally, reports in colorectal cancer patients demon-
strated a significantly improved time to progression and overall
survival for carriers of the GSTP1-105Val allele after 5-FU/
oxaliplatin chemotherapy (Stoehlmacher et al, 2002, 2004). In
contrast, McLeod et al (2003) did not observe a correlation
between the GSTP1-Ile105Val polymorphism and response to
oxaliplatin-based chemotherapy in colorectal cancer patients
(McLeod et al, 2003). These controversial results in colorectal
cancer may indicate a lower impact of the GSTP1-Ile105Val
polymorphism in oxaliplatin-based chemotherapy regimens.
Cabelguenne et al (2001) could not observe a correlation between
GSTP1 genotypes and response to cisplatin neoadjuvant chemo-
therapy in head and neck squamous cell cancer (HNSCC) patients.
However, they described that low plasmatic GSTP1 levels conferred
to a 2.3-fold increased relative risk of complete response in HNSCC
patients (Cabelguenne et al, 2001).
In summary, the results we report here are in strong agreement
with the current understanding of GSTP1 involvement in cisplatin
detoxification. Our findings support the hypothesis that increased
cisplatin sensitivity may in part be due to impaired GSTP1 enzyme
function. However, a critical review of our results in conjunction
with the current literature revealed that analysis of only the GSTP1
polymorphism does not represent a valid approach to distinguish
responders from nonresponders to a combination chemotherapy
of 5-FU and cisplatin. Reasons are the static character that is
inherent to a polymorphism and the complexity of metabolising
Table 3 Association between GSTP1-105 genotype and response to 5-
FU/cisplatin chemotherapy in patients with advanced gastric cancer
Responders Nonresponders
Total (n) No. % No. %
Genotype
Val/Val 6 4 67 2 33
Val/Ile +
Ile/Ile 42 9 21 33 79
P¼0.038 (Fisher’s exact test, two-sided) for genotype – response association.
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Figure 1 Association between GSTP1-105 genotypes and overall
survival in patients with advanced gastric cancer.
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Figure 2 Association between combined analyses of GSTP1-105 and
TS-50 UTR polymorphisms including the TS-50 G-C SNP and overall
survival among patients with advanced gastric cancer. Group A includes
patients with only unfavourable genotypes in both genes (n¼15). Group B
includes either patients homozygous for the GSTP1-105 Val variant or
patient with a favourable TS-50 UTR genotype (n¼23) and group C
patients are homozygous for GSTP1-105 Val and possess a favourable
TS-50 UTR polymorphism (n¼3).
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ssteps for chemotherapeutics. Therefore, we investigated a panel of
nine genes involved in 5-FU and cisplatin metabolism.
Considering the known interactions between GST genotypes, we
also analysed GSTM1 and GSTT1 genotypes, but did not find any
correlation with clinical characteristics. Polymorphisms in ERCC1
and ERCC2 also did not show any correlation with clinical
outcome in this study. One reason for this result maybe the limited
number of patients in the retrospective analysis.
For a more accurate prediction of response and survival to the
combination treatment of 5-FU and cisplatin, we also aimed to
explore possible associations between polymorphisms in fluoro-
pyrimidine metabolism and clinical outcome.
The active metabolites of fluoropyrimidines exert their anti-
tumour activity mainly through TS inhibition. This reaction is
facilitated by the formation of a ternary complex consisting of TS,
5,10-Methylene THF and 5-fluoro-dUMP (Peters et al, 2002). There
is growing evidence for functionally important polymorphic
variations within the TS gene. The 28-bp repeat and the G/C
SNP within the 50 UTR of the gene as well as the 6bp deletion
polymorphism in the 30 UTR, all have been described to alter
expression of TS (Pullarkat et al, 2001; Kawakami and Watanabe,
2003; Mandola et al, 2003, 2004). In the current study, patients who
possessed a TS 50 genotype associated with low TS mRNA
expression levels (Mandola et al, 2003) demonstrated a trend for
superior survival time compared with patients harbouring TS
genotypes known to be associated with high TS mRNA expression.
This observation is in agreement with recent findings by Marcuello
et al (2004) who revealed a significant association between clinical
outcome to 5-FU-based chemotherapy in colorectal cancer and TS
polymorphisms only if both TS polymorphisms within the 50 UTR
were analysed in conjunction (Marcuello et al, 2004). A trend
between TS polymorphism and clinical outcome was observed by
Ishida et al (2002) in gastric cancer patients who received oral
fluoropyrimidine therapy. However, the authors did not include
the novel G/C SNP that functionally transfers a TS 3R genotype
into a TS 2R genotype in their analysis. Although the observed
association between TS polymorphisms and outcome in our study
did not reach significance, the results support the hypothesis that a
comprehensive analysis of these TS polymorphisms is needed if
associations between TS polymorphisms and response to fluoro-
pyrimidine chemotherapy is explored. The reason that the
observed effect did not reach statistical significance may be again
due to the small number of patients.
Based on these findings, favourable and unfavourable genotype
groups were defined to describe the clinical outcome to 5-FU/
cisplatin combination chemotherapy in gastric cancer. We could
demonstrate that a patient’s benefit of 5-FU/cisplatin chemo-
therapy significantly increases with the number of favourable
genotypes. A combined analysis may more accurately identify
patients with maximum benefit from therapy. Although the
number of patients possessing two favourable genotypes was small
in our study their median survival time reached almost 24 months.
These findings, if confirmed, may have a significant impact on the
management of gastric cancer patients, since alternative drug
combinations are becoming available.
Our study is limited by both its retrospective nature and the
relatively small sample size. In addition, meanwhile more
polymorphic genes involved in platinum and 5-FU metabolism
have been identified (e.g. ERCC1-C8092A, MTHFR-A1298C), that
may also impact the effect of these drugs. To confirm our findings
from this pilot study and to improve the predictive value of
pharmacogenetic analyses in gastric cancer patients, we are
currently analysing a panel of 26 polymorphisms in genes of
metabolising and DNA repair enzymes in a large, randomised,
prospective phase III trial in advanced gastric cancer, involving
more than 220 patients.
To conclude, this pilot study demonstrated that combined
genotype analysis of GSTP1, TS-50 28bp and TS-50 G-C
polymorphisms may contribute to the selection of gastric cancer
patients who would benefit most from 5-FU/cisplatin combination
chemotherapy. To our knowledge, this is the first report
demonstrating a predictive value of GSTP1 genotypes in regard
to 5-FU/cisplatin combination chemotherapy in gastric cancer
patients.
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